Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 9/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7147181 | 0.92 | POLB (0.47) | POLBCTRB1CTSKCTSLCTSS | |
| SCHEMBL7144595 | 0.86 | POLB (0.48) | POLBCTRB1CTSKCTSSACE2 | |
| SCHEMBL7150573 | 0.85 | OPRM1 (0.54) | CTRB1MME | |
| SCHEMBL7960534 | 0.83 | POLB (0.43) | POLBCTRB1CTSKCTSLCTSS | |
| SCHEMBL7150010 | 0.83 | POLB (0.47) | POLBCTRB1 | |
| SCHEMBL7148259 | 0.83 | CTRB1 (0.54) | POLBCTRB1CTSKCTSL | |
| SCHEMBL24513611 | 0.82 | CTRB1 (0.64) | CTRB1CTSKCTSLACE2 | |
| SCHEMBL11167627 | 0.82 | CTRB1 (0.64) | CTRB1CTSKCTSLACE2 | |
| SCHEMBL11167632 | 0.82 | CTRB1 (0.64) | CTRB1CTSKCTSLACE2 | |
| SCHEMBL11450738 | 0.82 | CTRB1 (0.64) | CTRB1CTSKCTSLACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6541638-B2 | (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction | HOFFMAN-LA ROCHE INC. | 2003-04-01 | — | — | US | disclosed |
| US-20020049243-A1 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049243-A1 | Pyrrolidine derivatives | PREP, PEPD, DNPEP | POLB 1465/4885CTRB1 283/4885CTSK 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.